Literature DB >> 9495199

Urticaria pigmentosa: a clinical, hematopathologic, and serologic study of 30 adults.

G Topar1, C Staudacher, F Geisen, C Gabl, F Fend, M Herold, R Greil, P Fritsch, N Sepp.   

Abstract

Urticaria pigmentosa (UP) is the most common form of cutaneous mastocytosis and may be associated with systemic involvement, most often of the bone marrow. The incidence of systemic involvement is not yet well established, however. To address this question, we subjected a group of 30 adults with histologically proved UP to a retrospective study that included history, physical examination, laboratory tests including cytokine measurements, radiologic examinations, and bone marrow biopsies. The most frequently associated clinical symptoms were recurrent flush episodes in 16 of 30 patients, alcohol intolerance in 13, pruritus in 10, and gastrointestinal problems in 11 (recurrent diarrhea, 8 patients; gastritis, 2 patients; and history of peptic ulcer, 1 patient). Of the 30 patients, 18 (60%) had mast cell infiltrates of the bone marrow (nodular type, 10 patients; diffuse interstitial type, 8 patients). Bone marrow involvement was not correlated with massive cutaneous mast cell infiltration, clinically or histologically, or with the incidence of clinical symptoms and associated hematologic disorders. None of the patients had experienced progression of clinical symptoms, skin or organ involvement, or development of hematologic malignant neoplasms since UP was first diagnosed (10 years on average). Urticaria pigmentosa was found associated with mast cell infiltration of the bone marrow in 18 patients (60%). However, bone marrow involvement does not seem to predict adverse clinical course.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9495199     DOI: 10.1093/ajcp/109.3.279

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  7 in total

1.  ["Smoldering systemic mastocytosis. "Successful therapy with cladribine].

Authors:  V Schleyer; S Meyer; M Landthaler; R-M Szeimies
Journal:  Hautarzt       Date:  2004-07       Impact factor: 0.751

2.  Mastocytosis: the great masquerader.

Authors:  James S W Kong; Suzanne Teuber; Rosemary Hallett; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2006-02       Impact factor: 8.667

3.  A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients.

Authors:  Leona A Doyle; Golrokh J Sepehr; Matthew J Hamilton; Cem Akin; Mariana C Castells; Jason L Hornick
Journal:  Am J Surg Pathol       Date:  2014-06       Impact factor: 6.394

4.  Role of Mast Cells in the Pathogenesis of Pruritus in Mastocytosis.

Authors:  Dominika Kwiatkowska; Adam Reich
Journal:  Acta Derm Venereol       Date:  2021-10-31       Impact factor: 3.875

Review 5.  Contemporary challenges in mastocytosis.

Authors:  H David Pettigrew; Suzanne S Teuber; James S Kong; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

6.  Ileal Pouch Biopsy Triggers Investigation and Diagnosis of Systemic Mastocytosis.

Authors:  Abul Ala Syed Rifat Mannan; Bo Shen; Fred Hsieh; Deepa T Patil
Journal:  ACG Case Rep J       Date:  2016-08-03

Review 7.  Pharmacological treatment options for mast cell activation disease.

Authors:  Gerhard J Molderings; Britta Haenisch; Stefan Brettner; Jürgen Homann; Markus Menzen; Franz Ludwig Dumoulin; Jens Panse; Joseph Butterfield; Lawrence B Afrin
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-04-30       Impact factor: 3.000

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.